Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Next Previous
Trial Profile

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adagrasib (Primary) ; Afatinib (Primary) ; Cetuximab (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Registrational; Therapeutic Use
  • Acronyms KRYSTAL; KRYSTAL-01; KRYSTAL-1
  • Sponsors Mirati Therapeutics

    • Most Recent Events

    • 09 Apr 2024 Planned End Date changed from 1 Sep 2024 to 1 Jan 2026.
    • 09 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jul 2025.
    • 08 Apr 2024 According to a Bristol Myers Squibb media release,company announced that data will be featured in an oral presentation at the 2024 American Association for Cancer Research (AACR) annual meeting on Monday, April 8 at 11:10 a.m. Pacific Time and will be highlighted as part of the meetings official press program. The data will also be published simultaneously in Cancer Discovery .
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top